Device Trial Radar · NCT07257224
Post-market Clinical Follow-up Study of an Isotonic Saline Solution for the Relief of Nasal Congestion in Infants and Toddlers
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
83
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2027
Study completion Nov 2027
Sponsor
- Lead sponsor
- Laboratoires Quinton International S.L.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 2, 2025
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 6 months, up to 48 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this observational post-market clinical follow-up study is to evaluate the safety and performance of the CE-marked nasal spray for the relief of nasal congestion in infants and toddlers aged 6 to 48 months at day 5 post-enrollment. Enrollment does not require establishing a medical diagnosis; eligibility is based on guardian-reported nasal congestion consistent with lay use of the device. Participants will be: * Evaluated by a healthcare professional for eligibility. * Receive treatment with the CE-marked nasal spray according to its Instructions for Use, for up to 14 days. * Have their legal guardians report symptom severity and improvement using standardized scales (Visual Analog Scale) during follow-up visits on Day 2, Day 5, and Day 14 and device usability on Day 14. This study does not include a comparison group and reflects real-world use of the device in routine pediatric care.
Conditions
- Nasal Congestion
- Common Cold
- Allergic Rhinitis
- Rhinosinusitis
- Flu Symptom
Interventions
Quinton Medical Nasal Health Baby®Device
CE-marked Class IIa isotonic seawater nasal spray intended for nasal hygiene and relief of nasal congestion in infants and toddlers. In this study, the device will be administered according to its Instructions for Use, up to 6 applications per day, for a maximum of 14 days. Participants will be evaluated at Day 2, Day 5, and Day 14 for symptom relief, nasal discharge clearance, breathing improvement, sleep quality, and safety outcomes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety - Treatment-related AEs and SAEs at Day 5 Performance - Improvement in nasal congestion improvement indicators at Day 5Time frame: Baseline to Day 5
- Functioning - Symptom improvement at Day 5Time frame: Baseline to Day 5
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Clínica Uner
Alicante, Spain
Nombre de Mujer
Alicante, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.